NASDAQ:PTI Proteostasis Therapeutics (PTI) Stock Price, News & Analysis → Exposed: 10 CENT Crypto to Explode May 20th? (From True Market Insiders) (Ad) Free PTI Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.46▼$0.4950-Day Range$1.00▼$22.4252-Week Range$0.87▼$2.72Volume108,913 shsAverage Volume1.04 million shsMarket Capitalization$25.00 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsTrendsStock AnalysisCompetitorsTrends Get Proteostasis Therapeutics alerts: Email Address Ad Stansberry ResearchBUY ALERT: Tiny tech play partners with US governmentThe Federal Reserve is rolling out a powerful new financial technology across the entire U.S. banking system. It's forecasted to grow 24,290% in the near future... Meaning, your bank is nearly certain to adopt it (if it hasn't already).Get the full story here while you can. About Proteostasis Therapeutics Stock (NASDAQ:PTI)Proteostasis Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat cystic fibrosis. The company's lead product candidates for the treatment of CF include PTI-801, a cystic fibrosis transmembrane conductance regulator (CFTR) corrector agent; PTI-808, a CFTR potentiator; and PTI-428, a CFTR amplifier. It has collaboration agreements with Cystic Fibrosis Foundation, Inc. to research, develop, and commercialize products for the treatment of CF, non-classical CF, and other pulmonary diseases in the United States or the European Union; and Genentech, Inc. for licensing the technology and materials relating to therapeutic small molecule modulators. The company was formerly known as Proteoguard, Inc. and changed its name to Proteostasis Therapeutics, Inc. in September 2007. Proteostasis Therapeutics, Inc. was founded in 2006 and is headquartered in Boston, Massachusetts.Read More Ad Stansberry ResearchBUY ALERT: Tiny tech play partners with US governmentThe Federal Reserve is rolling out a powerful new financial technology across the entire U.S. banking system. It's forecasted to grow 24,290% in the near future... Meaning, your bank is nearly certain to adopt it (if it hasn't already).Get the full story here while you can. PTI Stock News HeadlinesApril 24, 2024 | globenewswire.comHarness Therapeutics Appoints Seasoned Biopharmaceutical Leader, Ms. Meenu Chhabra Karson, as Board ChairJuly 20, 2023 | bizjournals.comGreensboro joins incentive offers for $55M Honda expansion at PTI; Guilford County up nextMarch 13, 2023 | bloomberg.comFederal Police Summons India Minister in Bribery Probe, PTI SaysOctober 6, 2022 | nj.com7 years later, probation and PTI for pair in North Bergen low-show/no-show job schemeOctober 26, 2021 | finance.yahoo.comImplied Volatility Surging for Proteostasis Therapeutics (PTI) Stock OptionsSee More Headlines Receive PTI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Proteostasis Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/16/2020Today5/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:PTI CUSIPN/A CIK1445283 Webwww.proteostasis.com Phone617-225-0096FaxN/AEmployees44Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.16) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-59,130,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-75.39% Return on Assets-55.04% Debt Debt-to-Equity RatioN/A Current Ratio6.69 Quick Ratio6.69 Sales & Book Value Annual Sales$5 million Price / Sales5.00 Cash FlowN/A Price / Cash FlowN/A Book Value$1.22 per share Price / Book0.39Miscellaneous Outstanding Shares52,185,000Free FloatN/AMarket Cap$25.00 million OptionableNot Optionable Beta1.16 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMs. Meenu Chhabra (Age 48)Pres, CEO & Director Comp: $844.78kDr. Marija Zecevic (Age 46)Chief Commercial Officer Comp: $530.46kMichael L. AlfieriHead of Fin.Dr. Benito Munoz (Age 58)Chief Scientific Officer Ms. Janet L. Smart Esq. (Age 63)Ph.D., J.D., Sr. VP of Legal Affairs Dr. Geoffrey S. Gilmartin (Age 52)Chief Medical Officer Ms. Claudia StyslingerInvestor Relations Exec.More ExecutivesKey CompetitorsAssertioNASDAQ:ASRTTiziana Life SciencesNASDAQ:TLSAConnect BiopharmaNASDAQ:CNTBYS BiopharmaNASDAQ:YSEton PharmaceuticalsNASDAQ:ETONView All Competitors PTI Stock Analysis - Frequently Asked Questions How were Proteostasis Therapeutics' earnings last quarter? Proteostasis Therapeutics, Inc. (NASDAQ:PTI) released its quarterly earnings results on Monday, November, 16th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.17) by $0.01. What other stocks do shareholders of Proteostasis Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Proteostasis Therapeutics investors own include Idera Pharmaceuticals (IDRA), BHP Group (BHP), Sorrento Therapeutics (SRNE), OPKO Health (OPK), Amarin (AMRN), Matinas BioPharma (MTNB), Micron Technology (MU), Rite Aid (RAD), VBI Vaccines (VBIV) and Acasti Pharma (ACST). When did Proteostasis Therapeutics IPO? Proteostasis Therapeutics (PTI) raised $51 million in an IPO on Thursday, February 11th 2016. The company issued 3,900,000 shares at $12.00-$14.00 per share. Leerink Partners and RBC Capital Markets acted as the underwriters for the IPO and Baird and H.C. Wainwright & Co. were co-managers. This page (NASDAQ:PTI) was last updated on 5/30/2024 by MarketBeat.com Staff From Our PartnersExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceWrite this ticker symbol down…StocksToTradeThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarBiden Nomination CANCELED?The Freeport SocietyBUY ALERT: Tiny tech play partners with US governmentStansberry ResearchGold Set to EXPLODE!Gold Safe Exchange[Urgent!] Generational Wealth GameplanCrypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Proteostasis Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.